Synovus Financial Corp Purchases 3,038 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Synovus Financial Corp grew its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 13.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 25,639 shares of the medical equipment provider's stock after purchasing an additional 3,038 shares during the period. Synovus Financial Corp's holdings in Lantheus were worth $2,294,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Wilmington Savings Fund Society FSB bought a new position in Lantheus in the third quarter valued at about $25,000. Kestra Investment Management LLC acquired a new stake in shares of Lantheus in the 4th quarter valued at approximately $27,000. Summit Securities Group LLC bought a new stake in shares of Lantheus during the 4th quarter valued at approximately $37,000. UMB Bank n.a. increased its position in Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after purchasing an additional 134 shares in the last quarter. Finally, World Investment Advisors LLC bought a new position in Lantheus in the 3rd quarter valued at approximately $60,000. Institutional investors and hedge funds own 99.06% of the company's stock.

Wall Street Analyst Weigh In

LNTH has been the topic of a number of research reports. Truist Financial boosted their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. JMP Securities reaffirmed a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Finally, B. Riley cut their price target on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Lantheus has a consensus rating of "Moderate Buy" and an average target price of $129.43.

Insiders Place Their Bets

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 63,109 shares of company stock worth $6,016,046. 1.50% of the stock is currently owned by insiders.

Lantheus Price Performance

NASDAQ LNTH traded up $0.80 on Friday, reaching $101.32. The company had a trading volume of 430,521 shares, compared to its average volume of 954,628. The firm has a market cap of $6.94 billion, a price-to-earnings ratio of 16.86 and a beta of 0.20. Lantheus Holdings, Inc. has a fifty-two week low of $62.59 and a fifty-two week high of $126.89. The business has a 50 day moving average of $95.39 and a two-hundred day moving average of $95.38.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The company had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. As a group, research analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.